-
FDA approves Merck’s Keytruda for patients who have a specific biomarker
WASHINGTON — The Food and Drug Administration on Tuesday granted accelerated approval to a treatment for patients whose cancers have a specific genetic feature (biomarker). This is the first time the agency has approved a cancer treatment based on a common biomarker rather than the location in the body where the tumor originated.